Drug Approval | April 14, 2026
FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Highlights Mirvetuximab-based regimen promise
Spread across nearly 4,500 sq. ft., the new clinic combines advanced dental technology, experienced specialists, and an Atithi-first care model
The three-day conference is expected to bring together more than 3,000 physiotherapists, clinicians, researchers, academicians, and students
The event also featured discussions on emerging trends in joint replacement surgery
The improved score reflects a stronger ESG profile for the Ahmedabad-based drugmaker
The FDA clearance of Zeto New Wave marks the company’s third cleared device, alongside Zeto WR19 and Zeto ONE
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
Subscribe To Our Newsletter & Stay Updated
